Due to their proficiency at antigen cross-presentation (i.e., the presentation to both CD4+ and CD8+ T cells), DC have been used as vaccine platforms to induce anti-tumor cytotoxic T lymphocyte (CTL) CD8 immune responses (5–8). This evidence concerns the gene CD8A and neoplasm.